Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 17 (3) , e505-e512
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal NeoplasiaAmerican Journal of Surgical Pathology, 2013
- Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma in the Tyrosine Kinase Inhibitor Era? A Multi-institutional StudyUrology, 2013
- The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal CancerEuropean Urology, 2011
- The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor ThrombusEuropean Urology, 2011
- Radical nephrectomy with vena caval thrombectomy: a contemporary experienceBJU International, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigmBJU International, 2008
- Neoadjuvant Therapy with Sorafenib in Advanced Renal Cell Carcinoma with Vena Cava Extension Submitted to Radical NephrectomyUrologia Internationalis, 2008
- Surgery Insight: management of renal cell carcinoma with associated inferior vena cava thrombusNature Reviews Endocrinology, 2008
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003